Literature DB >> 6870220

Vancomycin pharmacokinetics in patients with peritonitis on peritoneal dialysis.

B E Magera, J C Arroyo, S J Rosansky, B Postic.   

Abstract

Vancomycin pharmacokinetics were studied in four patients with peritonitis undergoing chronic intermittent peritoneal dialysis. Serum levels exceeding 4.0 micrograms/ml were maintained for 8 and 13 days after a single 1-g intravenous dose. Vancomycin serum concentrations measured before, during, and upon completion of dialysis revealed no appreciable decline. Peritoneal fluid concentrations in two patients exceeded 4.0 micrograms/ml for more than 12 days.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6870220      PMCID： PMC184793          DOI： 10.1128/AAC.23.5.710

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  4 in total

1.  Rapid microassay of gentamicin, kanamycin, neomycin, streptomycin, and vancomycin in serum or plasma.

Authors:  L D Sabath; J I Casey; P A Ruch; L L Stumpf; M Finland
Journal:  J Lab Clin Med       Date:  1971-09

Review 2.  Vancomycin revisited.

Authors:  F V Cook; W E Farrar
Journal:  Ann Intern Med       Date:  1978-06       Impact factor: 25.391

3.  Vancomycin for staphylococcal shunt site infections in patients on regular haemodialysis.

Authors:  S Eykyn; I Phillips; J Evans
Journal:  Br Med J       Date:  1970-07-11

4.  Peritoneal clearance and total body elimination of vancomycin during chronic intermittent peritoneal dialysis.

Authors:  J C Ayus; J F Eneas; T G Tong; N L Benowitz; P Y Schoenfeld; K L Hadley; C E Becker; M H Humphreys
Journal:  Clin Nephrol       Date:  1979-03       Impact factor: 0.975
  4 in total
  10 in total

1.  Toxicologic and pharmacokinetic evaluation of a case of vancomycin intoxication during continuous ambulatory peritoneal dialysis.

Authors:  Y A Hekster; T B Vree; C M Weemaes; J J Rotteveel
Journal:  Pharm Weekbl Sci       Date:  1986-12-12

Review 2.  Drug therapy in patients undergoing peritoneal dialysis. Clinical pharmacokinetic considerations.

Authors:  T W Paton; W R Cornish; M A Manuel; B G Hardy
Journal:  Clin Pharmacokinet       Date:  1985 Sep-Oct       Impact factor: 6.447

3.  Vancomycin: renewed interest in an old drug.

Authors:  B B Farber
Journal:  Eur J Clin Microbiol       Date:  1984-02       Impact factor: 3.267

4.  Distribution of ceftazidime in ascitic fluid.

Authors:  G Benoni; E Arosio; M G Raimondi; E Apolloni; E Passarella; A Lechi; G P Velo
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

5.  Comparison of fluorescence polarization immunoassay and bioassay of vancomycin.

Authors:  D J Pohlod; L D Saravolatz; M M Somerville
Journal:  J Clin Microbiol       Date:  1984-08       Impact factor: 5.948

6.  Pharmacokinetics of vancomycin in patients undergoing continuous ambulatory peritoneal dialysis.

Authors:  R D Blevins; C E Halstenson; N G Salem; G R Matzke
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

7.  Intraperitoneal vancomycin concentrations during peritoneal dialysis-associated peritonitis: correlation with serum levels.

Authors:  Richard Fish; Robert Nipah; Chris Jones; Hazel Finney; Stanley L S Fan
Journal:  Perit Dial Int       Date:  2011-11-01       Impact factor: 1.756

Review 8.  Clinical pharmacokinetics of vancomycin.

Authors:  G R Matzke; G G Zhanel; D R Guay
Journal:  Clin Pharmacokinet       Date:  1986 Jul-Aug       Impact factor: 6.447

9.  Vancomycin pharmacokinetics in patients with various degrees of renal function.

Authors:  K A Rodvold; R A Blum; J H Fischer; H Z Zokufa; J C Rotschafer; K B Crossley; L J Riff
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

10.  Comparative study of intraperitoneal and intravenous vancomycin pharmacokinetics during continuous ambulatory peritoneal dialysis.

Authors:  G D Morse; D F Farolino; M A Apicella; J J Walshe
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.